The effect of Eudragit type on BSA-loaded PLGA nanoparticles

Abstract

Poly(d,l-lactide-co-glycolide) nanoparticle (PLGA NP) have been broadly studied as a carrier for drug delivery system of peptides and proteins. However, negative surface charge of PLGA NP using only PLGA decreases bioavailability under oral administration. In this study, novel carriers for oral delivery system through an additional bioadhesive polymer, Eudragit was introduced. Our purpose is to prepare PLGA NP using bovine serum albumin (BSA) as a model drug and Eudragit and evaluate their physiochemical characteristics, eventually expand to peptide and protein drug such as insulin or exenatide. In this study, PLGA NP were spherical and the size was around 400–500 nm. The encapsulation efficiency (EE) of PLGA NP when prepared with only PLGA was the highest, approximately 95.3 %. The polydispersity index values were low approximately 0.1, which meant their size was regular. In mucoadhesion test, we knew PLGA NP prepared by using Eudragit RS or Eudragit RL had a high affinity to mucin particles through zeta-potential change of mucin particle to cover their surface. Also, PLGA NP did not show cytotoxicity against Caco-2 cells. Especially, BSA-loaded PLGA NP using Eudragit RS 100 prepared had high EE, low polydispersity index, spherical shape having a smooth surface, sustained release profile, non-cytotoxicity and bioadhesive effect.